Asia Pacific Microbiome Diagnostics Market Size, Share & Trends Analysis Report By Application, By Product (Reagents & Kits and Instruments), By Sample (Fecal, Saliva, Skin, and Others), By Technology, By End User, By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Microbiome Diagnostics Market would witness market growth of 18.7% CAGR during the forecast period (2023-2030).

The China market dominated the Asia Pacific Microbiome Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $24,054 Thousands by 2030. The Japan market is registering a CAGR of 18.1% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 19.7% during (2023 - 2030).



There is a growing trend towards consumer-oriented microbiome diagnostics, driven by consumer demand for personalized health information and wellness solutions. Direct-to-consumer (DTC) testing services, mobile health applications, and wearable devices empower individuals to assess their microbiome health, monitor wellness trends, and make informed lifestyle choices. Consumers utilize microbiome diagnostics to gain insights into their gut health, metabolic function, immune function, and skin health, guiding dietary modifications, probiotic supplementation, and lifestyle interventions. Adopting consumer-oriented microbiome diagnostics reflects a shift towards proactive and participatory approaches to health and wellness, empowering individuals to take charge of their health.

Moreover, one of microbiome diagnostics’ most prominent applications is assessing gastrointestinal health. It can provide insights into conditions such as inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), celiac disease, and colorectal cancer by analyzing the composition and diversity of microbial communities in the gut. Understanding the gut microbiome’s role in digestive health and disease can guide personalized treatment strategies and dietary interventions.

The expansion of the pharmaceutical industry in China is driving a shift towards personalized medicine approaches that consider individual variations in disease susceptibility, treatment response, and microbiome composition. China’s pharmaceutical industry is predicted to develop steadily and reach $161.8 billion in 2023, accounting for around 30% of the market. Thus, the region’s growing pharmaceutical and medical devices industries propel the market’s growth.

Based on Application, the market is segmented into Disease Diagnostics (Gastrointestinal Disorders, Metabolic Diseases and Others) and Research Application. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Sample, the market is segmented into Fecal, Saliva, Skin, and Others. Based on Technology, the market is segmented into 16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics and Others. Based on End User, the market is segmented into Hospitals, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

• Illumina, Inc.
• Becton, Dickinson and Company
• Genetic Analysis AS
• Microba Life Sciences Limited
• BioMe Oxford Ltd
• Viome Life Sciences, Inc.
• GoodGut S.L.U. (HIPRA, S.A.)
• Sun Genomics
• Origin Sciences Limited
• Decode Age

Market Report Segmentation

By Application

• Disease Diagnostics
• Gastrointestinal Disorders
• Metabolic Diseases
• Others
• Research Application

By Product

• Reagents & Kits
• Instruments

By Sample

• Fecal
• Saliva
• Skin
• Others

By Technology

• 16S rRNA Sequencing
• Shot Gun Metagenomics
• Metatranscriptomics
• Others

By End User

• Hospitals
• Academic & Research Institutes
• Biotechnology & Pharmaceutical Companies

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific